Contemporary management of advanced chronic kidney disease: An evidence-based review
- 23 October 2025
- journal article
- review article
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 143, 106557
Abstract
No abstract availableKeywords
Funding Information
- Mayo Clinic
- Zell Family Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases (U54 DK144863)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK142878)
This publication has 96 references indexed in Scilit:
- Intraarterial Autologous Mesenchymal Stem Cell Therapy for Diabetic Kidney DiseaseKidney International Reports, 2025
- U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT TrialJACC: Advances, 2025
- Autosomal Dominant Polycystic Kidney DiseaseJAMA, 2025
- Finerenone: First ApprovalDrugs, 2021
- Tolvaptan in ADPKD Patients With Very Low Kidney FunctionKidney International Reports, 2021
- A Systematic Review and Meta-Analysis of Cell-Based Interventions in Experimental Diabetic Kidney DiseaseStem Cells Translational Medicine, 2021
- Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialEuropean Journal of Heart Failure, 2021
- Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation StudyEBioMedicine, 2016
- Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenoneInternational Journal of Cardiology, 2015
- Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney DiseaseDrugs, 2015